Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Ming J. Poi"'
Autor:
Nathan D. Seligson, Xunjie Zhang, Mark C. Zemanek, Jasmine A. Johnson, Zachary VanGundy, Danxin Wang, Mitch A. Phelps, Julianna Roddy, Craig C. Hofmeister, Junan Li, Ming J. Poi
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2024)
Introduction: Polymorphisms in genes responsible for the metabolism and transport of tacrolimus have been demonstrated to influence clinical outcomes for patients following allogeneic hematologic stem cell transplant (allo-HSCT). However, the clinica
Externí odkaz:
https://doaj.org/article/74d23d0d6a3644e1ac4dd5f599fa8963
Autor:
Melissa Thomas, Junan Li, Kevan King, Avinash K Persaud, Ernest Duah, Zachary Vangundy, Craig C. Hofmeister, Jatinder K. Lamba, Aik Choon Tan, Brooke L. Fridley, Ming J. Poi, Nathan D. Seligson
Publikováno v:
Haematologica, Vol 108, Iss 8 (2023)
Multiple Myeloma (MM) is an incurable plasma cell malignancy often treated by autologous stem cell transplant (ASCT). Clinical response to ASCT has been associated with DNA repair efficiency. Here we interrogated the role of the base excision DNA rep
Externí odkaz:
https://doaj.org/article/7a7b8d3edef349908f93a513689d97de
Autor:
Junan, Li, Yu Kyoung, Cho, Douglas W, Sborov, Mitch A, Phelps, Craig C, Hofmeister, Ming J, Poi
Publikováno v:
Cancer Genomics Proteomics
Background/Aim: There exists considerably large interpatient variability in pharmacokinetic exposure of high dose melphalan in multiple myeloma patients with hematopoietic stem-cell transplantation. In this study, we aimed to evaluate the potential i
Autor:
JUNAN LI, AVINASH K. PERSAUD, JASMINE A. JOHNSON, DOUGKAS W. SBOROV, MITCH A. PHELPS, CRAIG C. HOFMEISTER, MING J. POI
Publikováno v:
Anticancer Research. 42:385-395
Autor:
Ming J, Poi, Junan, Li, Jasmine A, Johnson, Yu Kyoung, Cho, Douglas W, Sborov, Mitch A, Phelps, Craig C, Hofmeister
Publikováno v:
Anticancer research. 39(1)
SLC7A5 is recognized as the major mediator of melphalan uptake into multiple myeloma (MM) cells; however, its contribution to the inter-patient variability of melphalan efficacy and toxicity is yet to be well elucidated. This study aimed to investiga
Publikováno v:
DNA repair. 57
The presence of an enhancer element, RD
Autor:
Ming J, Poi, Junan, Li, Douglas W, Sborov, Zachary, VanGundy, Yu Kyoung, Cho, Misty, Lamprecht, Flavia, Pichiorri, Mitch A, Phelps, Craig C, Hofmeister
Publikováno v:
Molecular carcinogenesis. 56(7)
Multiple myeloma (MM) is a hematologic malignancy characterized by clonal proliferation of plasma cells and overproduction of monoclonal immunoglobins. Treatment with melphalan is currently standard of care for younger and fit patients when followed
Autor:
Bhuvaneswari Ramaswamy, Robert Wesolowski, Ming J. Poi, Rachel M. Layman, Ewa Mrozek, Erin M. Olson, Charles L. Shapiro, Maryam B. Lustberg, Michael Berger
As the result of a recent national shortage in paclitaxel, some patients who were receiving or scheduled to receive weekly paclitaxel were converted to every 3-week (q3w) docetaxel with granulocyte colony-stimulating factor support. Our institution n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd95dec42e5a0f8531dcbd9da846d438
https://europepmc.org/articles/PMC3769512/
https://europepmc.org/articles/PMC3769512/
Publikováno v:
The FASEB Journal. 27
Autor:
Junan, Li, Thomas J, Knobloch, Ming J, Poi, Zhaoxia, Zhang, Andrew T, Davis, Peter, Muscarella, Christopher M, Weghorst
Publikováno v:
Molecular carcinogenesis. 53(3)
Recent identification of an enhancer element, RD(INK4/ARF) (RD), in the prominent INK4/ARF locus provides a novel mechanism to simultaneously regulate the transcription of p15(INK4B) (p15), p14(ARF) , and p16(INK4A) (p16) tumor suppressor genes. Whil